Dr. Kim's goal is to develop chimeric antigen receptor T cells as a safe and effective therapy for AML. To this end, I am exploring different target antigens for CAR T cell therapy, investigating mechanisms to enhance the anti-tumor effect of CAR T cells, and finding methods to circumvent the toxicity associated with T cell immunotherapy in the setting of myeloid malignancies.
Siteman Cancer Center:
4921 Parkview Pl, St. Louis, MO 63110, USA
Get the latest thought leadership on AML delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life
AML stories, AML clinical trials, AML 101 articles and events with AML
Thanks to our HealthTree Community for AML Sponsors: